Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 6719239, 6 pages
https://doi.org/10.1155/2017/6719239
Clinical Study

Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus

Diabetes Center, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Correspondence should be addressed to Triantafyllos Didangelos; rg.htua.dem@gnadid

Received 13 January 2017; Accepted 21 February 2017; Published 8 March 2017

Academic Editor: Ilias Migdalis

Copyright © 2017 Triantafyllos Didangelos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Tesfaye, A. J. Boulton, P. J. Dyck et al., “Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments,” Diabetes Care, vol. 33, pp. 2285–2293, 2010. View at Google Scholar
  2. J. E. Shaw and P. Z. Zimmet, “The epidemiology of diabetic neuropathy,” Diabetes Reviews, vol. 7, no. 4, pp. 245–252, 1999. View at Google Scholar · View at Scopus
  3. P. J. Dyck, W. J. Litchy, K. A. Lehman, J. L. Hokanson, J. L. Low, and P. C. O'Brien, “Variables influencing neuropathic endpoints: the rochester diabetic neuropathy study of healthy subjects,” Neurology, vol. 45, no. 6, pp. 1115–1121, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. A. I. Vinik and T. Erbas, “Diabetic autonomic neuropathy,” Handbook of Clinical Neurology, vol. 117, pp. 27–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Pop-Busui, W. H. Herman, E. L. Feldman et al., “DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history,” Current Diabetes Reports, vol. 10, no. 4, pp. 276–282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. L. Martin, J. W. Albers, and R. Pop-Busui, “Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study,” Diabetes Care, vol. 37, no. 1, pp. 31–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Ohkubo, H. Kishikawa, E. Araki et al., “Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study,” Diabetes Research and Clinical Practice, vol. 28, no. 2, pp. 103–117, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. American Diabetes Association and American Academy of Neurology, “Consensus statement: report and recommendations of the San Antonio Conference on Diabetic Neuropathy,” Diabetes Care, vol. 11, pp. 592–597, 1988. View at Google Scholar
  10. V. Spallone, D. Ziegler, R. Freeman et al., “Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 7, pp. 639–653, 2011. View at Publisher · View at Google Scholar
  11. D. Ziegler, G. Laux, K. Dannehl et al., “Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses,” Diabetic Medicine, vol. 9, no. 2, pp. 166–175, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. W. H. Herman, R. Pop-Busui, B. H. Braffett et al., “Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications,” Diabetic Medicine, vol. 29, no. 7, pp. 937–944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. G. Kontopoulos, V. G. Athyros, T. P. Didangelos et al., “Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy,” Diabetes Care, vol. 20, no. 3, pp. 355–361, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. T. P. Didangelos, G. A. Arsos, D. T. Karamitsos, V. G. Athyros, S. D. Georga, and N. D. Karatzas, “Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy,” Journal of Diabetes and its Complications, vol. 20, no. 1, pp. 1–7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Gæde, P. Vedel, N. Larsen, G. V. H. Jensen, H.-H. Parving, and O. Pedersen, “Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 348, no. 5, pp. 383–393, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Ziegler, P. A. Low, R. Freeman, H. Tritschler, and A. I. Vinik, “Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial,” Journal of Diabetes and Its Complications, vol. 30, no. 2, pp. 350–356, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Malik, S. Williamson, C. Abbott et al., “Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial,” Lancet, vol. 352, no. 9145, pp. 1978–1981, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Ziegler and D. Luff, “Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities?” International Review of Neurobiology, vol. 50, pp. 431–463, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. P. Davidson, L. J. Coppey, A. Holmes, and M. A. Yorek, “Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 677, no. 1–3, pp. 180–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. J. Coppey, E. P. Davidson, T. W. Rinehart et al., “ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats,” Diabetes, vol. 55, no. 2, pp. 341–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Papageorgiou, A. Karayiannis, V. Athyros, S. Douma, K. Petidis, and C. Zamboulis, “A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension,” Drug Investigation, vol. 7, no. 1, pp. 13–17, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. N. C. Chilelli, S. Burlina, and A. Lapolla, “AGEs, rather than hyperglycemia, are responsible formicrovascular complications in diabetes: a‘glycoxidation-centric’ point of view,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, no. 10, pp. 913–919, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Forbes, M. E. Cooper, V. Thallas et al., “Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy,” Diabetes, vol. 51, pp. 3274–3282, 2002. View at Google Scholar
  24. J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke et al., “Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2363–2372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. B. C. Callaghan, A. A. Little, E. L. Feldman, and R. A. C. Hughes, “Enhanced glucose control for preventing and treating diabetic neuropathy,” Cochrane Database of Systematic Reviews, vol. 6, Article ID CD007543, 2012. View at Google Scholar · View at Scopus
  27. T. P. Didangelos, D. T. Karamitsos, V. G. Athyros, and G. I. Kourtoglou, “Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years,” Journal of Diabetes and its Complications, vol. 12, no. 4, pp. 201–207, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Hu, S. Li, G. Yang, H. Liu, G. Boden, and L. Li, “Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 2, Article ID e87096, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Javed, U. Alam, and R. A. Malik, “Treating diabetic neuropathy: present strategies and emerging solutions,” Review of Diabetic Studies, vol. 12, no. 1-2, pp. 63–83, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Migdalis, G. Rombopoulos, M. Hatzikou, C. Manes, N. Kypraios, and N. Tentolouris, “The cost of managing type 2 diabetes mellitus in greece: a retrospective analysis of 10-year patient level data 'the HERCULES study',” International Journal of Endocrinology, vol. 2015, Article ID 520759, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus